Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II multinational clinical trial of brilacidin for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS)

Next Previous
Trial Profile

A Phase II multinational clinical trial of brilacidin for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 19 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brilacidin (Primary)
  • Indications Ulcerative proctitis; Ulcerative proctosigmoiditis
  • Focus Therapeutic Use
  • Sponsors Alfasigma

Most Recent Events

  • 13 May 2021 According to an Innovation Pharmaceuticals media release, Alfasigma plans to initiate this trial in 2021. Alfasigma has placed an order with the Company for Brilacidin drug substance needed for the trial.
  • 17 Dec 2019 New trial record
  • 10 Dec 2019 According to an Innovation Pharmaceuticals media release, this trial is expected to begin by mid-year 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top